O'Shaughnessy Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

O'Shaughnessy Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,817	Closed	-$233K	–	2660
2025 Q4	$233K	Buy	+10,817	New	+$210K	﹤0.01%	1911
2018 Q3	–	Sell	-37,067	Closed	-$227K	–	901
2018 Q2	$227K	Buy	37,067 +80	+0.2%	+$561	﹤0.01%	513
2018 Q1	$270K	Buy	36,987 +10,490	+40%	+$92.3K	0.01%	458
2017 Q4	$217K	Buy	+26,497	New	+$248K	0.01%	517

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

O'Shaughnessy Asset Management's AVDL Position: Q1 2026 in Review

O'Shaughnessy Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 10,817 shares — an estimated $233K sold.

O'Shaughnessy Asset Management first reported a position in AVDL in Q4 2017 and held it in 4 quarters. The position peaked at $270K in Q1 2018. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

O'Shaughnessy Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
O'Shaughnessy Asset Management sold 10,817 Avadel Pharmaceuticals shares in Q1 2026, an estimated $233K.
O'Shaughnessy Asset Management first reported a position in Avadel Pharmaceuticals in Q4 2017 and held it in 4 quarters.
O'Shaughnessy Asset Management's Avadel Pharmaceuticals position peaked at $270K in Q1 2018.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q1 2026, filed 13 May 2026.